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Patients with locally advanced lung cancer and very limited pulmonary function (forced expiratory volume in 1 second [FEV1] ≤ 
1 L) have dismal prognosis and undergo palliative treatment or best supportive care. We describe two cases of locally advanced 
node-positive non-small cell lung cancer (NSCLC) patients with very limited lung function treated with induction chemotherapy 
and moderate hypofractionated image-guided radiotherapy (Hypo-IGRT). Hypo-IGRT was delivered to a total dose of 45 Gy to the 
primary tumor and involved lymph nodes. Planning was based on positron emission tomography-computed tomography (PET/
CT) and four-dimensional computed tomography (4D-CT). Internal target volume (ITV) was defined as the overlap of gross tumor 
volume delineated on 10 phases of 4D-CT. ITV to planning target volume margin was 5 mm in all directions. Both patients showed 
good clinical and radiological response. No relevant toxicity was documented. Hypo-IGRT is feasible treatment option in locally 
advanced node-positive NSCLC patients with very limited lung function (FEV1 ≤ 1 L). 
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Introduction
Locally advanced node-positive lung cancer patients often 
present with limited lung function due to chronic pulmonary 
comorbidities. Because conventional thoracic irradiation and 
chemoradiotherapy (CRT) are associated with significant 
pulmonary toxicity, these high-risk patients undergo palliative 
treatment or best supportive care alone [1].
Stereotactic body radiotherapy (SBRT) is an established 
treatment option in early-stage inoperable non-small cell 
lung cancer (NSCLC) [2]. SBRT was also shown to be feasible 
and safe in patients with limited lung function. Furthermore, 
several small trials have demonstrated that accelerated 
hypofractionated thoracic irradiation can be safely delivered 
in locally advanced lung cancer [3,4]. Nevertheless, these small 
trials included patients with adequate pulmonary function 
exclusively. There is no data on the feasibility of multimodality 
treatment in locally advanced node-positive patients with 
reduced lung function 
Two high-risk patients with very limited lung function 
(forced expiratory volume in 1 second [FEV1] ≤ 1 L) and locally 
advanced node-positive disease were treated with induction 
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chemotherapy followed by hypofractionated image-guided 
radiotherapy (Hypo-IGRT). In the following report, we describe 
these cases with follow-up of 9 months.
Case Report
1. Patients
A 72-year-old woman (current non-smoker) with the Eastern 
Cooperative Oncology Group (ECOG) performance status 2 
presented with stage IIIA NSCLC. She had chronic obstructive 
pulmonary disease (COPD) Global Initiative for Chronic 
Obstructive Lung Disease (GOLD) III at baseline. Tumor-related 
symptoms included worsening of dyspnea. The histology was 
an adenocarcinoma of the lung, epidermal growth factor 
receptor (EGFR) wild-type without anaplastic lymphoma 
kinase (ALK)-translocation. 18F-FDG/PET-CT (positron emission 
tomography with 2-deoxy-2-[fluorine-18]-fluoro-D-glucose 
integrated with computed tomography) in treatment position 
showed the primary tumor with pleural contact in the right 
upper lobe and positive lymph nodes in the ipsilateral hilum 
and mediastinum. The pulmonary function tests revealed a 
vital capacity (VC) of 2.02 L, FEV1 of 1.0 L (60% predicted) and 
an estimated DLCO (diffusion capacity for carbon monoxide) 
of 35% of the norm. Induction chemotherapy constituting 
cisplatin 80 mg/m² IV (intravenous) day1 and pemetrexed 
500 mg/m² IV day1 (every 3 weeks) was initially administered, 
leading to stable disease. Two and a half months after the last 
cycle of chemotherapy, Hypo-IGRT was delivered.
A 62-year-old man (current non-smoker) with ECOG 
performance status 2 presented with stage IIIA NSCLC. He had 
COPD GOLD IV at baseline and was on supplemental oxygen. 
Tumor-related symptoms included pain in the parasternal 
region and worsening of dyspnea. The histology revealed an 
adenocarcinoma of the lung, EGFR wild-type without ALK-
translocation. FDG/PET-CT scan in treatment position showed 
the primary tumor with pleural contact in the left upper lobe 
and positive lymph nodes in the ipsilateral mediastinum. The 
pulmonary function tests revealed a VC of 2.66 L, FEV1 of 0.84 
L (56% predicted) and DLCO was not measurable. Induction 
chemotherapy was also administered analog the above-
mentioned case, leading to stable disease. Two months after 
the last cycle of chemotherapy, Hypo-IGRT was delivered.
2. Hypo-IGRT
Hypo-IGRT was performed fol lowing chemotherapy. 
Patients underwent PET-CT and four-dimensional computed 
tomography (4D-CT) (10 sequential scans in all respiratory 
phases) in the treatment position (vacuum pillow and alpha-
cradle). 4D-CT was matched with PET-CT for better definition 
of the target volume. The range of tumor motion was 1–4 
mm in every dimensional space. Gross tumor volume (GTV) 
included primary tumor and involved lymph nodes (short-
axis ≥1 cm and/or PET-positive) post-induction chemotherapy. 
Internal target volume (ITV) was defined through the overlap 
of GTVs delineated on 10 phases of 4D-CT. clinical target 
volume was not generated in both cases, due to much reduced 
pulmonary reserve. Isotropic margin of 5 mm was added to ITV 
to generate the planning target volume (PTV). PTV was 255.5 
and 314.28 cm3 in patient #1 and #2, respectively. Dose was 
calculated in 3 mm grid with Collapse-Cone algorithm (Fig. 1).
Total dose to PTV was 45 Gy in 15 fractions, 5 times a 
week and was prescribed per ICRU with corrections for lung 
inhomogeneity. Pulmonary dose-volume parameters were 
calculated with total lung volume minus PTV. Mean lung dose 
(MLD), averages of the ipsilateral and contralateral lung were 
10.6 Gy, 14.45 Gy, and 4.98 Gy in patient #1 and 9.4 Gy, 13.99 
Gy, and 5.17 Gy in patient #2, respectively. In the first patient, 
V5 and V10 of both lungs were 52% and 32%, respectively. In 
the second patient, V5 and V10 were 48% and 29%. V20 (both 
lungs) was 19.1% and 15% in patients #1 and #2, respectively. 
Radiation was delivered by linear accelerator (Elekta Synergy, 
Stockholm, Sweden) using 15 MeV 8–9 coplanar fixed photon 
beams. Image guidance was performed with kilovoltage-cone-
beam CT prior to each treatment. Toxicity monitoring was 
performed twice weekly to record any side effects.
3. Treatment tolerability
The first patient presented with grade 2 esophagitis (Common 
Terminology Criteria for Adverse Events v4.0) during last 4 
days of treatment. Hypo-IGRT was not interrupted and the 
symptoms were resolved 5 days following irradiation. Lung 
function after treatment was at 1 month VC/FEV1/DLCO 1.87 
L/0.88 L (53.6% predicted)/27.4%; at 3 months 1.73 L/0.98 
L (59.8% predicted)/no data; and at 6 months 1.65 L/0.88 L 
(55% predicted)/27.0%, respectively. No symptoms relative to 
radiation pneumonitis (CT thorax 6 weeks and 3 months post-
radiation) and/or worsening of the baseline COPD-related 
symptoms were observed. The Patient achieved good partial 
response and she is progression-free after 9 months follow-
up. Lung function at 9-month follow-up revealed VC/FEV1/
DLCO 1.61 L/0.98 L (59.9% predicted)/22%.
The second patient presented with an acute COPD 
exacerbation during the first week of Hypo-IGRT. Immediate 
hospitalization with application of systemic antibiotics and 
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steroids was necessary. He developed grade 2 esophagitis 
at the end treatment, which was self-limiting after 3 weeks. 
Hypo-IGRT was interrupted for 3 days. Convalescence 
occurred 4 days following hospitalization. Lung function 
following treatment with bronchodilators, steroids, oxygen 
und pulmonary rehabilitation therapy was at 1 month VC/
FEV1/DLCO 2.22 L/0.93 L (30.8% of predicted)/not measurable 
and at 3 months with 2.16 L/0.86 L (28.4% predicted)/not 
measurable. Pulmonary function test at 6 months was refused 
by the patient. No symptoms of radiation pneumonitis on CT 
and/or worsening of the baseline COPD-related symptoms 
were observed. Partial response was achieved and remained 
stable, but distant progression after 6 months follow-up was 
documented and second-line chemotherapy was initiated.
DISCUSSION
The present case report demonstrates that moderate Hypo-
IGRT can be considered as a feasible treatment in locally 
advanced NSCLC patients with very limited lung function. 
An important requirement of our radiation treatment was an 
accurate transfer of SBRT technique for early-stage lung cancer 
to these high-risk node-positive patients. We have chosen a 
moderate dose prescription concept with overall duration of 
3 weeks (15 fractions at 3 Gy per fraction once daily, 5 times 
a week) and corresponding biologically effective dose 10 Gy 
(BED α/β-ratio 10 Gy assumed) of 58.5 Gy according to Amini 
et al. [3]. Local effectiveness of this moderate accelerated 
hypofractionated protocol was previously extensively 
described [3,4]. Important prerequisites referring to the 
treatment planning were also maximal accepted MLD and V20 
(both lungs) of 10 Gy and 20% to significantly reduce the risk 
of symptomatic pneumonitis [5–7]. Both patients completed 
Hypo-IGRT with good partial response and complete regression 
of the tumor-related symptoms. Although we observed a 
mild decline of the pulmonary function parameters (Table 1) 
3 to 6 months after Hypo-IGRT, no worsening of the baseline 
COPD-related symptoms and radiation pneumonitis were 
documented. 
Chiang et al. [8] reported the effectiveness and feasibility of 
Fig. 1. Isodose distribution in selected planning computed tomography slices in patient #1 (A) and patient #2 (B), respectively.
A
B
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hypofractionated radiotherapy in multimorbid patients with 
early-stage NSCLC without lymph node involvement but not 
for locally-advance node-positive NSCLC as described in the 
above-mentioned cases.
A study by He et al. [9] analyzed a subgroup of patients with 
limited pulmonary function, who received hypofractionated (60 
Gy in 20 fractions) CRT via helical tomotherapy and showed 
good response without an increase in treatment-related 
toxicity.
Furthermore, previous studies have shown that conventional 
radiotherapy was associated with significant alterations 
in patient pulmonary function. Apart from tumor-related 
morbidity, residual pulmonary function is a major determinant 
of patient condition and survival. A previous study in locally 
advanced NSCLC treated with definitive CRT found only 8 
months survival in patients with pronounced lung function 
deficits (VC <60%, FEV1 <80% predicted, DLCO <60%) vs. 16 
months in patients with adequate pulmonary function [10]. 
An analysis from Gopal et al. [11] in 100 lung cancer patients 
treated with CRT revealed a 1.3% DLCO decline for each 1% of 
total lung volume that received >20 Gy.   Borst et al. [12] also 
found a significant decrease in the lung function parameters 
starting at 3 months after definitive CRT.
In the last decade, several groups investigated poor baseline 
pulmonary function in patients with early-stage NSCLC treated 
with SBRT and demonstrated that this condition should not be 
used to exclude patients from treatment [13]. Moderate decline 
in lung function parameters were revealed 6 to 24 months 
after SBRT. In addition, Guckenberger et al. [14] reported an 
improvement of parameters in a subgroup of patients with 
worse pre-treatment pulmonary function. Another analysis 
has failed to demonstrate any dose-response relationship for 
the reduction of function parameters after SBRT.
In conclusion, our case report demonstrates that moderate 
Hypo-IGRT can be considered in locally advanced node-
positive NSCLC patients with very limited lung function but 
careful patient selection and monitoring as well as experience 
with SBRT technique are important prerequisites. Prospective 
studies for the evaluation of safety and efficacy of this 
approach are urgently necessary; we are currently planning a 
prospective study pending approval from the ethics committee 
of the Ludwig-Maximilians University of Munich.
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